Torrent Pharmaceuticals experienced a 4.7% increase in its share price on the Bombay Stock Exchange (BSE), reaching an intra-day high of ₹4,698.8 following the release of its Q4FY26 results. Despite a 21.9% decline in consolidated net profit to ₹389 crore, attributed to a 37% increase in expenses, the company reported a 42% rise in revenue from operations, totaling ₹4,197 crore. The growth was driven largely by strong domestic performance, with revenues in India increasing by 43% to ₹2,215 crore. Brokerages have mixed opinions on the integration of JB Chemicals and Pharmaceuticals (JBCP). Nomura maintained a neutral stance, citing a significant earnings miss due to unexpected amortization costs and exceptional losses. Meanwhile, Motilal Oswal and JM Financial expressed optimism, with Motilal raising its target price to ₹4,400 and JM Financial increasing it to ₹5,423, both highlighting robust growth prospects in various markets. The management anticipates continued growth in India and other international markets, supported by synergies from the JBCP acquisition.